A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

The following contains links to social media websites including Bluesky, X, TikTok, Instagram, Facebook, and LinkedIn. "Make ...

Although reports of vision problems with weight loss drugs are still rare, researchers say there is cause for concern because ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.

Related Cosmetic surgeons try to correct 'Ozempic face' for weight-loss drug users Massive study looks at benefits, risks of GLP-1 weight-loss drugs FDA says shortage of GLP-1 drug tirzepatide is ...